Renal Risks of an Emerging "Epidemic" of Obesity: The Role of Adipocyte-Derived Factors

Dialysis and Transplantation

Volumn 33, Issue 1, 2004, Pages 11-21

  Saxena, Anil K ^a   Chopra, Rajan ^b  

^a Division of Nephrology   (Saudi Arabia)

^b KING FAHAD HOSPITAL   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA TOCOPHEROL; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA CAROTENE; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LEPTIN; PROSTACYCLIN DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE AGENT;

ADIPOCYTE; BLOOD PRESSURE; DIALYSIS; DISEASE COURSE; EDEMA; FOCAL GLOMERULOSCLEROSIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; WEIGHT REDUCTION;

EID: 0346789098     PISSN: 00902934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. James PT, Leach R, Kalamara E, Shayeghi M. The worldwide obesity epidemic. Obes Res 2001; 9:228-233.
2. Buckland Y. The obesity epidemic. J Fam Health Care 2002; 12(4):111.
3. World Health Organization. Obesity: Preventing and managing the global epidemic. Geneva: WHO, 1998.
4. Adelman RD. Obesity and renal disease. Curr Opin Nephrol Hypertens 2002; 11(3):331-335.
5. Sorisky A. Molecular links between obesity and cardiovascular disease. Am J Ther 2002; 9(6):516-521.
6. Hall JE, Crook ED, Jones DW, Wofford MR, Dubbert PM. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002; 324(3):127-137.
7. Kasike BL, Crosson JT. Renal disease in patients with massive obesity. Arch Intern Med 1086; 146(6):1105-1109.
8. Adelman RD, Restaino IG, Alon US, Blowey DL. Proteinuria and focal segmental glomerulosclerosis in severely obese adolescents. J Pediatr 2001; 138(4):481-485.
9. Maddox DA, Alavi FK, Silbernick EM, Zawada ET. Protective effects of a soy diet in preventing obesity-linked renal disease. Kidney Int 2002; 61(1):96-104.
10. Wardle EN. Soy protein diet therapy in renal disease. Nephron 1998; 78(3):328-31.
11. Mather KJ, Mirza Mohammedi B, Lteif A, Steinberg HO, Baron AD. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type-II diabetes. Diabetes 2002; 51(12):3517-3523.
12. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62(5):1524-1538.
13. McIntyre M, Bohr DF, Dominczak AF. Endothelial function in hypertension. Hypertens 1999; 34:539-545.
14. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculatures. Circ Res 1999; 85:753-766.
15. Kitiyakara C, Gonin J, Massy Z, Wilcox CS. Non-traditional cardiovascular disease risk factors in end-stage renal disease: Oxidative stress and hyperhomocysteinemia. Curr Opin Nephrol Hypertens 2000; 9:477-487.
16. Olusi SO. Obesity is an independent risk factor for plasma lipid peroxidation and depletion of erythrocyte cytoprotective enzymes in humans. Int J Obes Relat Metab Disord 2002; 26(9):1159-1164.
17. Wilcox CS. Reactive oxygen species: Roles in blood pressure and kidney function. Curr Hypertens Rep 2002; 4(2):160-166.
18. Hall JE, Brandy MW, Henegar JR, Shek EW. Abnormal kidney function as a cause and a consequence of obesity hypertension. Clin Exp Pharmacol Physiol 1998; 25:58-64.
19. Sugerman HJ. Effects of increased intraabdominal pressure in severe obesity. Surg Clin North Am 2001; 81(5):1063-1075.
20. West DB, Wehberg KE, Kieswetter K, Granger JP. Blunted natriuretic response to an acute sodium load in obese hypertensive dogs. Hypertension 1992; 19:196-200.
21. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. Glomerular hemodynamics in severe obesity. Am J Physiol 2000; 278:817-822.
22. Baldwin DS. Chronic glomerulonephritis: Non-immunologic mechanism of progressive glomerular disease. Kidney Int 1982; 21:109-120.
23. Cediel E, Vazquez-Cruz B, Navarro-Cid J, De Las Heras N, Sanz-Rosa D, Cachofeiro V, Lahera V. Role of endothelin-1 and thromboxane A2 in renal vasoconstriction induced by angiotensin II in diabetes and hypertension. Kidney Int 2002; 82:2-7.
24. Myers BD, Boothroyd D, Olshen RA. Angiotensin-converting enzyme inhibitor for slowing progression of diabetic and nondiabetic kidney disease. J Am Soc Nephrol 1998; 9:S66-S70.
25. Zanella MT, Kohlmann O Jr, Ribeiro AB. Treatment of obesity hypertension and diabetes syndrome. Hypertension 2001; 38:705-708.
26. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelial-dependent vasodilatation by restoring nitric oxide activity in essential hypertension. Circulation 1998; 97:2222-2229.
27. De Jong PE, Verhave JC, Pinto-Sietsma SJ, Hillege HL, for the PREVEND Study group. Obesity and target organ damage: The kidney. Int J Obes Relat Metab Disord 2002; 26:21-24.
28. Liese AD, Hense HW, Doring A, Stieber J, Keil U. Microalbuminuria, central adiposity and hypertension in the non-diabetic urban population of the MONICA Augsburg survey 1994/95. J Hum Hypertens 2001; 15(11):799-804.
29. Sasatomi Y, Tada M, Uesugi N, Hisano S, Takebayashi S. Obesity associated with hypertension or hyperlipidemia accelerates renal damage. Pathobiology 2001; 69(2):113-118.
30. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: An emerging epidemic. Kidney Int 2001; 59(4):1498-1509.
31. Praga M, Hernandez E, Morales E, et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant 2001; 9:1790-1798.
32. Cohen AH. Pathology of renal complications in obesity. Curr Hypertens Rep 1999; 1(2):137-139.
33. Verani RR. Obesity-associated focal segmental glomerulosclerosis: pathological features of the lesion and relationship with cardiomegaly and hyperlipidemia. Am J Kidney Dis 1992; 20(6):629-634.
34. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 1988; 33(3):667-672.
35. Bonnet F, Deprele C, Sassolas A, et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 2001; 37(4):720-727.
36. Kuiper JJ. Effects of weight reduction and angiotensin-converting enzyme inhibition on IgA nephropathy-associated proteinuria. Nephron 1996; 74(2):462-463.
37. Manuel P. Obesity: A neglected culprit in renal disease. Nephrol Dial Transplant 2002; 17:1157-1159.
38. Boeing H, Schlehofer B, Wahrendorf J. Diet, obesity and risk for renal cell carcinoma: Results from a case control-study in Germany. Z Ernahrungswiss 1997; 36(1):3-11.
39. Moyad MA. Review of potential risk factors for kidney (renal cell) cancer. Semin Urol Oncol 2001; 19(4):280-293.
40. Gago-Dominguez M, Castelao JE, Yuan JM, Ross RK, Yu MC. Lipid peroxidation: A novel and unifying concept of the etiology of renal cell carcinoma (United States). Cancer Causes Control 2002; 13 (3):287-293.
41. Moyad MA. Obesity, interrelated mechanisms, and exposures and kidney cancer. Semin Urol Oncol 2001; 19(4):270-279.
42. Allon M, Ornt DB, Schwab SJ, et al. Factors associated with the prevalence of arteriovenous fistulas in hemodialysis patients in the HEMO Study. Hemodialysis (HEMO) Study Group. Kidney Int 2000; 58(5):2178-2185.
43. Saxena AK, Panhotra BR, Naguib M, et al. The impact of achieving the target goal for AV fistulas, as set by NKF-DOQI, on Staphylococcus aureus septicemia. Dial Transplant 2002; 31:16-23.
44. Weyde W, Krajewska M, Letachowicz W, Klinger M. Superficialization of the wrist native arteriovenous fistula for effective hemodialysis vascular access construction. Kidney Int 2002; 61(3):1170-1173.
45. Piraino B, Bernardini J, Centa PK, Johnston JR, Sorkin MI. The effect of body weight on CAPD-related infections and catheter loss. Perit Dial Int 1991; 11(1):64-68.
46. Querques M, Strippoli GF, Dell'Aquila R, Gallucci M, Di Iorio B, Manno C. Gruppo di Studio Apulo-Lucano sulla Nutrizione [Prevalence of obesity in hemodialysis patients from Puglia and Lucania]. G Ital Nefrol 2002; 19(4):432-438.
47. Salahudeen AK, Fleischmann EH, Bower JD. Impact of lower delivered Kt/V on the survival of overweight patients on hemodialysis. Kidney Int 1999; 56(6):2254-2259.
48. Tzamaloukas AH, Murata GH. Peritoneal dialysis in patients with large body size: Can it deliver adequate clearances? Perit Dial Int 1999; 19(5):409-414.
49. Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW. Body mass index and mortality in 'healthier' as compared with 'sicker' hemodialysis patients: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2001; 12:2386-2394.
50. Johnson DW, Herzig KA, Purdie DM, et al. Is obesity a favorable prognostic factor in peritoneal dialysis patients? Perit Dial Int 2000; 20(6):715-721.
51. Meier-Kriesche HU, Vaghela M, Thambuganipalle R, Friedman G, Jacobs M, Kaplan B. The effect of body mass index on long-term renal allograft survival. Transplantation 1999; 68(9):1294-1297.
52. Yamamoto S, Hanley E, Hahn AB, et al. The impact of obesity in renal transplantation: An analysis of paired cadaver kidneys. Clin Transplant 2002; 16(4):252-256.
53. Meier-Kriesche HU, Arndorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: A significant independent risk factor for graft failure and patient death. Transplantation 2002; 73(1):70-74.
54. Bumgardner GL, Henry ML, Elkhammas E, et al. Obesity as a risk factor after combined pancreas/kidney transplantation. Transplantation 1995; 60(12):1426-1430.
55. Modlin CS, Flechner SM, Goormastic M, et al. Should obese patients lose weight before receiving a kidney transplant? Transplantation 1997; 64(4):599-604.
56. Shibata N, Hoshino N, Minouchi T, Yamaji A, Park K, Tomoyoshi T, Abe H, Kodama M. Relationship between area under the concentration versus time curve of cyclosporin A, creatinine clearance, hematocrit value, and other clinical factors in Japanese renal transplant patients. Int J Clin Pharmacol Ther 1998; 36(4):202-209.
57. Johnson DW, Isbel NM, Brown AM, et al. The effect of obesity on renal transplant outcomes. Transplantation 2002; 74(5):675-681.
58. Teplan V, Poledne R, Schuck O, Ritz E, Vitko S. Hyperlipidemia and obesity after renal transplantation. Ann Transplant 2001; 6(2):21-23.
59. Wiecek A, Kokot F, Chudek J, Adamczak M. The adipose tissue: A novel endocrine organ of interest to the nephrologist. Nephrol Dial Transplant 2002; 17:191-195.
60. Sharma K, Considine RV. The Ob protein (leptin) and the kidney. Kidney Int 1998; 53(6):1483-1487.
61. Wolf G, Hamann A, Han DC, et al. Leptin stimulates proliferation and TGF-β expression in renal glomerular endothelial cells: Potential role in glomerulosclerosis. Kidney Int 1999; 56(3):860-872.
62. Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis 2002; 39(1):1-11.
63. Koo JR, Pak KY, Kim KH, et al. The relationship between plasma leptin and nutritional status in chronic hemodialysis patients. J Korean Med Sci 1999; 14(5):546-551.
64. Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome: The heart of the matter. Nephrol Dial Transplant 2002; 17(11):28-31.
65. Nordfors L, Lonnqvist F, Heimburger O, Danielsson A, Schalling M, Stenvinkel P. Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int 1998; 54(4):1267-1275.
66. Wiesholzer M, Harm F, Hauser AC, Pribasnig A, Balcke P. Inappropriately high plasma leptin levels in obese hemodialysis patients can be reduced by high-flux hemodialysis and hemodiafiltration. Clin Sci 1998; 94(4):431-435.
67. Kagan A, Haran N, Leschinsky L, Shuali N, Rapoport J. Leptin in CAPD patients: Serum concentrations and peritoneal loss. Nephrol Dial Transplant 1999; 14(2):400-405.
68. Kagan A, Haran N, Leschinsky L, et al. Serum concentrations of leptin in heart, liver and kidney transplant recipients. Isr Med Assoc J 2002; 3:213-217.
69. Landt M, Brennan DC, Parvin CA, Flavin KS, Dagogo-Jack S, Coyne DW. Hyperleptinemia of end-stage renal disease is corrected by renal transplantation. Nephrol Dial Transplant 1998; 13(9):2271-2275.
70. Kokot F, Adamczak M, Wiecek A. Plasma leptin concentration in kidney transplant patients during the early post-transplant period. Nephrol Dial Transplant 1998; 13(9):2276-2280.
71. Okatomo Y, Arita Y, Nishida M et al. An adipose-derived plasma protein, adiponectin, adheres to the injured vascular walls. Horm Metab Res 2000; 32:47-50.
72. Ouchi N, Kihara S, Arita Y, et al. Novel modulator on endothelial adhesion molecules, adipocyte-derived plasma protein adiponectin. Circulation 1999; 100:2473-2476.
73. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86:1930-1935.
74. Hotto K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20:1595-1599.
75. Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13(1):134-141.
76. Mallamaci F, Zoccali C, Cuzzola F, et al. Adiponectin in essential hypertension. J Nephrol 2002; 15(5):507-511.
77. Ukkola O. Resistin: A mediator of obesity-associated insulin resistance or an innocent bystander? Eur J Endocrinol 2002; 147(5):571-574.
78. Steppan CM, Baily ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 18:307-312.
79. Song H, Shojima N, Sakoda S. Resistin is regulated by C/EBPs, PPARs, and signal-transducing molecules. Biochem Biophys Res Commun 2002; 299(2):291-298.
80. Yu JG, Javorschi S, Hevener, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002; 51(10):2968-2974.
81. Karlsson C. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab 1998; 83:3925-3929.
82. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor-α: A key component of obesity-diabetes link. Diabetes 1994; 43:1271-1278.
83. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance and endothelial function. A potential role for cytokines originating from adipose tissue. Arterioscler Thromb Vasc Biol 1999; 19:972-978.
84. Bottinger EP, Bitzer M. TGF-β signaling in renal disease. J Am Soc Nephrol 2002; 13(10):2600-2610.
85. Mauro Abbate, Carla Zoja, Marina Morigi, et al. Transforming growth factor-β1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: A central pathway in progressive glomerulosclerosis. Am J Pathology 2002; 161:2179-2193.
86. Schiffer M, Bitzer M, Roberts IS, et al. Apoptosis in podocytes induced by TGF-β and Smad7. J Clin Invest 2001; 108(6):807-816.
87. Dahly AJ, Hoagland KM, Flasch AK, Jha S, Ledbetter SR, Roman RJ. Antihypertensive effects of chronic anti-TGF-β antibody therapy in Dahl S rats. Am J Physiol Regul Integr Comp Physiol 2002; 283(3):757-767.
88. Segarra A, Chacon P, Martinez-Eyarre C, et al. Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: Biochemical correlation and role as independent predictors of coronary artery stenosis. J Am Soc Nephrol 2001; 12:1255-1263.
89. Stern JS, Gades MD, Wheeldon CM, Borchers AT. Calorie restriction in obesity: Prevention of kidney disease in rodents. J Nutr 2001; 131(3):913-917.
90. Wardle EN. Antioxidants in the prevention of renal disease. Ren Fail 1999; 21(6):581-591.